Filing Details

Accession Number:
0001209191-16-119992
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-05-13 16:58:58
Reporting Period:
2016-05-11
Filing Date:
2016-05-13
Accepted Time:
2016-05-13 16:58:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055949 D Samuel Isaly 601 Lexington Avenue; 54Th Floor
New York NY 10022
Yes No No No
1055951 Orbimed Advisors Llc 601 Lexington Avenue; 54Th Floor
New York NY 10022
Yes No No No
1615374 Orbimed Capital Gp V Llc 601 Lexington Avenue; 54Th Floor
New York NY 10022
Yes No No No
1673892 Orbimed Global Healthcare Gp Llc 601 Lexington Avenue; 54Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-05-11 1,847,400 $0.00 1,847,400 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-05-11 564,780 $0.00 2,412,180 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-05-11 191,466 $18.00 2,603,646 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-05-11 58,534 $18.00 2,662,180 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2016-05-11 2,857,143 $0.00 1,847,400 $0.00
Common Stock Series B Preferred Stock Disposition 2016-05-11 873,475 $0.00 564,780 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series B Preferred Stock was automatically converted into 0.6465903 of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
  2. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V. OrbiMed Advisors LLC ("Advisors") is the managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI V and as a result may be deemed to have beneficial ownership over such securities.
  3. This report on Form 4 is jointly filed by GP V, OGH GP, Advisors, and Mr. Isaly. Each of the Reporting Persons disclaims beneficial ownership ofthe securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"),except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Carl L.Gordon, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  4. These securities are held of record by OrbiMed Global Healthcare Master Fund L.P. ("OGH"). OrbiMed Global Healthcare GP LLC ("OGH GP") is the sole general partner of OGH. Advisors is the managing member of OGH GP. Isaly, a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, OGH GP, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OGH and as a result may be deemed to have beneficial ownership over such securities.
  5. Not applicable.